Who are brinzolamide 1% ophthalmic suspension's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sodium Nitrite, Banzel, Tri-Luma, Azopt, Trusopt, Fludara.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brinzolamide-1-ophthalmic-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

brinzolamide 1% ophthalmic suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

brinzolamide 1% ophthalmic suspension (brinzolamide 1% ophthalmic suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor. Area: Ophthalmology.

phase 3 Carbonic anhydrase inhibitor Carbonic anhydrase Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

brinzolamide 1% ophthalmic suspension (brinzolamide 1% ophthalmic suspension) — Bausch & Lomb Incorporated. Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
brinzolamide 1% ophthalmic suspension TARGET	brinzolamide 1% ophthalmic suspension	Bausch & Lomb Incorporated	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase
Sodium Nitrite	SODIUM NITRITE	Hope Pharms	marketed	sodium nitrite	Carbonic anhydrase 1	2011-01-01
Banzel	RUFINAMIDE	Eisai	marketed	rufinamide	Carbonic anhydrase 5A, mitochondrial	2008-01-01
Tri-Luma	HYDROQUINONE	Galderma Labs Lp	marketed	Melanin Synthesis Inhibitor [EPC]	Carbonic anhydrase 2	2002-01-01
Azopt	BRINZOLAMIDE	Novartis	marketed	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
Trusopt	DORZOLAMIDE	Merck & Co.	marketed	Carbonic Anhydrase Inhibitor	Carbonic anhydrase 2	1994-01-01
Fludara	FLUDARABINE PHOSPHATE	Nihon Schering K.K.	marketed	Nucleoside Metabolic Inhibitor	Carbonic anhydrase 5A, mitochondrial	1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor class)

Bausch & Lomb Incorporated · 2 drugs in this class
Actavis Inc. · 2 drugs in this class
Beijing Tiantan Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National University Hospital, Singapore · 1 drug in this class
Padagis LLC · 1 drug in this class
Rabin Medical Center · 1 drug in this class
Shahid Beheshti University of Medical Sciences · 1 drug in this class
Sun Pharmaceutical Industries Limited · 1 drug in this class
University Health Network, Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). brinzolamide 1% ophthalmic suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/brinzolamide-1-ophthalmic-suspension. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab